SCHEMBL3535940

SCHEMBL3535940

Cc1oc(C(=O)NS(=O)(=O)c2ccccc2)cc1C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 8/20 0.58
HPGD P15428 2/20 0.52
ALDH1A1 P00352 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
KDM4E B2RXH2 1/20 0.49
EGFR P00533 1/20 0.47
METAP2 P50579 2/20 0.47
FLT1 P17948 1/20 0.47
FLT4 P35916 1/20 0.47
KDR P35968 1/20 0.47
PTGS1 P23219 2/20 0.47
PTGS2 P35354 2/20 0.47
ALKBH2 Q6NS38 1/20 0.45
ALKBH5 Q6P6C2 1/20 0.45
FTO Q9C0B1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12991398 0.78 PTGER4 (0.67) PTGER4HPGDALDH1A1
SCHEMBL10765828 0.74 KDM4E (0.72) HPGDALDH1A1L3MBTL1KDM4EEGFR
SCHEMBL3534150 0.74 PTGER4 (1.00) PTGER4
SCHEMBL3534146 0.74 PTGER4 (0.59) PTGER4HPGDALDH1A1KDM4EFLT1
SCHEMBL3540821 0.73 PTGER4 (1.00) PTGER4
SCHEMBL3535945 0.72 KDM4E (0.52) PTGER4HPGDKDM4EEGFRFLT1
SCHEMBL653805 0.71 FLT1 (0.77) HPGDALDH1A1KDM4EEGFRFLT1
SCHEMBL1412654 0.71 POLB (0.71) HPGDKDM4EEGFRFLT1FLT4
SCHEMBL13841825 0.70 PTGER4 (0.68) PTGER4HPGDALDH1A1L3MBTL1KDM4E
SCHEMBL28176964 0.70 RAB9A (0.56) HPGDALDH1A1L3MBTL1KDM4EPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100408570-C EP4 receptor antagonists PHARMAGENE LAB LTD (GB) 2008-08-06 CN claimed
EP-1603893-B1 EP4 RECEPTOR ANTAGONISTS ASTERAND UK LTD (GB) 2008-05-21 EP claimed
US-7858644-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2010-12-28 US disclosed
US-20090143437-A1 EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2009-06-04 US disclosed
US-7528157-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2009-05-05 US disclosed
US-7507754-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2009-03-24 US disclosed
CN-100408570-C EP4 receptor antagonists PHARMAGENE LAB LTD (GB) 2008-08-06 CN disclosed
EP-1603893-B1 EP4 RECEPTOR ANTAGONISTS ASTERAND UK LTD (GB) 2008-05-21 EP disclosed
US-20080039502-A1 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2008-02-14 US disclosed
US-20070123575-A1 EP4 RECEPTOR ANTAGONISTS ASTERAND UK ACQUISITION LIMITED (GB) 2007-05-31 US disclosed
US-7196089-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2007-03-27 US disclosed
CN-1761657-A EP4 receptor antagonists PHARMAGENE LAB LTD (GB) 2006-04-19 CN disclosed
EP-1603893-A1 EP4 RECEPTOR ANTAGONISTS Pharmagene Laboratories Ltd (GB) 2005-12-14 EP disclosed
US-20040192767-A1 EP4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2004-09-30 US disclosed
WO-2004067524-A1 EP4 RECEPTOR ANTAGONISTS PHARMAGENE LABORATORIES LIMITED (GB) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143437-A1 EP4 RECEPTOR ANTAGONISTS PTGER4, NR4A1, NR4A2 PTGER4 1/4885HPGD 618/4885ALDH1A1 1522/4885
US-20040192767-A1 EP4 receptor antagonists PTGER4, PTGER1, NR4A1 PTGER4 1/4885HPGD 621/4885ALDH1A1 1258/4885
US-20070123575-A1 EP4 RECEPTOR ANTAGONISTS PTGER4, NR4A1, PTGER1 PTGER4 1/4885HPGD 628/4885ALDH1A1 1424/4885
US-20080039502-A1 EP4 receptor antagonists PTGER4, NR4A1, PTGER1 PTGER4 1/4885HPGD 645/4885ALDH1A1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.